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Abstract
Background: An association has been suggested between gout and erectile dysfunction (ED), however studies
quantifying the risk of ED amongst gout patients are lacking. We aimed to precisely determine the population-level
absolute and relative rate of ED reporting among men with gout over a decade in England.
Methods: We utilised the UK-based Clinical Practice Research Datalink to identify 9653 men with incident gout
age- and practice-matched to 38,218 controls. Absolute and relative rates of incident ED were calculated using Cox
regression models. Absolute rates within specific time periods before and after gout diagnosis were compared to
control using a Poisson regression model.
Results: Overall, the absolute rate of ED post-gout diagnosis was 193 (95% confidence interval (CI): 184–202) per
10,000 person-years. This corresponded to a 31% (hazard ratio (HR): 1.31 95%CI: 1.24–1.40) increased relative risk
and 0.6% excess absolute risk compared to those without gout. We did not observe statistically significant differences in
the risk of ED among those prescribed ULT within 1 and 3 years after gout diagnosis. Compared to those unexposed,
the risk of ED was also high in the year before gout diagnosis (relative rate = 1.63 95%CI 1.27–2.08). Similar findings were
also observed for severe ED warranting pharmacological intervention.
Conclusions: We have shown a statistically significant increased risk of ED among men with gout. Our findings will have
important implications in planning a multidisciplinary approach to managing patients with gout.
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Background
Gout is the most prevalent type of inflammatory arth-
ritis, affecting 2.4% of adults in the UK. It is largely man-
aged in primary care [1] and is associated with a number
of comorbidities [2, 3]. Erectile dysfunction (ED) is also
a common problem in the general population affecting
2% of men aged under 40 years rising to 86% of those
aged over 80 years [4]. Recently, an association between
gout and ED had been suggested based on one small
hospital-based cross-sectional study [5] and two cohort
studies from Southeast Asia [6, 7]. Whilst the latter
studies were based on large administrative data, their
findings can only be generalised to western countries
with caution, given the large variation in the reporting of
ED by region [4]. Furthermore, the causal relationship
between gout and ED demonstrated in one previous
study failed to account for important factors including
body mass index (BMI), smoking status and alcohol con-
sumption, which may have confounded the association
[6]. Finally, to our knowledge no previous study has
quantified the incidence of ED warranting pharmaco-
logical intervention or assessed ED reporting both before
and after gout diagnosis, which may be important in
understanding disease mechanisms. Knowledge about
gout-associated comorbidities is crucial for planning
multidisciplinary approaches to disease management.
Therefore, the aim of this study was to precisely determine
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the population level absolute and relative rates of ED
reporting among men with gout over a decade in the UK.
Methods
The Clinical Practice Research Datalink (CPRD) [8] is a
large longitudinal UK database that contains compu-
terised primary care (i.e. general practice) records of
anonymised patients. Approximately 98% of the England
and Wales population are registered with general practi-
tioners (GPs), who are responsible for almost the entir-
ety of a patient’s medical care, including coordination of
their health care from a hospital or other secondary care
facilities. The CPRD includes practices that have re-
ceived training to record information using Vision soft-
ware and that have consented to be included in the
database. All patients within a consented practice are
automatically included. CPRD is subjected to various
quality checks and a practice’s data is only used when it
is of the highest quality to be used for research. This is
denoted by defining an up-to-standard (UTS) time
period for each practice. For the purpose of this study,
we utilised a subset of CPRD linked to Hospital Episode
Statistics, which records England’s secondary care data.
The HES-linked CPRD have been compared to the Of-
fice of National Statistics (ONS) data showing similar
age and sex distribution [9].
We identified men aged 18–64 years with a first-ever
recorded diagnosis of gout from general practice be-
tween 1998 and 2004 who were then followed up until
2015. The study start date was defined as the latest of
study start date (1 January 1998), date of patient regis-
tration with the practice and UTS date. The study end
date was defined as the earliest of the date of last data
collection from the practice, date patient transferred out
from practice or died, and the study end date (31 August
2015). Gout diagnosis was based on a medical code
assigned by the physician which has been previously val-
idated in CPRD with a positive predictive value of 90%
[10]. Each patient was assigned an index date corre-
sponding to the date of their gout diagnosis and ran-
domly matched to four controls on age (±3 years)
without gout or a prescription for urate-lowing therapy
(ULT) who were registered at the same practice, and
were alive and contributing data at the index date. Con-
trols were assigned the same index date as their matched
gout case. Those with less than a year of follow-up, his-
tory of prior ED diagnosis, or prescribed ED-specific
medication in the absence of a diagnostic code during
the study period were excluded. For our primary ana-
lysis, we looked at the rate of ED reporting after the
index date (for cases and controls). In order to assess
how ED reporting rates varied in relation to the time of
gout diagnosis, we also analysed all available person-
time before the index date. Thus we were able to look at
patients who developed ED before their gout diagnosis
and subsequently excluded from our primary analysis.
Incident ED reporting was based on medical codes
assigned by the physician during the study period. In
order to ensure incident reporting, those assigned an ED
code in the first 6 months of their registration with the
practice were classified as prevalent cases and were ex-
cluded from our post-gout analysis. We only assessed the
incidence of the first ED and therefore any subsequent ED
events (along with the follow-up time) were excluded
from the study. We defined pharmacologically treated ED
based on those who were prescribed pharmacological
treatment for ED any time after their initial diagnosis.
We extracted information on lifestyle-related charac-
teristics (BMI, smoking status and alcohol consumption)
and specific comorbidities (ischemic heart disease,
hypertension, diabetes mellitus, depression and chronic
renal disease) for both cases and controls. BMI was cate-
gorised as normal weight (18.5–25 kg/m2), underweight
(≤18.5 kg/m2), overweight (>25– 29.9 kg/m2) and obese
(≥30 kg/m2). Covariate information was ascertained
using the most recent measure before the outcome or
study end date.
Patient characteristics were compared between cases
and controls using frequencies and percentages. Chi-
squared tests were conducted to quantify statistically sig-
nificant differences between cases and controls. We cal-
culated the incidence of ED as the number of first-
recorded ED diagnoses per 10,000 person-years. Ad-
justed hazard ratio (HR) and 95% confidence interval
(CI) was calculated using a Cox regression model to
compare the hazard rate between cases and controls. Ro-
bust standard errors were used to account for matching.
To explore potential interaction by lifestyle-related char-
acteristics and comorbidities, we stratified our analyses
by those covariates. Those with missing information on
BMI were categorised as a separate category and were
included in the analysis. We assessed the timing of ED
reporting in relation to gout diagnosis by comparing the
absolute rate of ED before and after gout diagnosis
among cases and controls in terms of incidence rate ra-
tios using a Poisson regression model. We utilised land-
mark analysis to examine the effect of ULT on the risk
of ED [11]. This method deals with immortal time bias
which biases the results in favour of the treatment under
study by granting a spurious survival advantage to the
treated group. In landmark analysis [12], a fixed time
after the initiation of therapy is selected a priori for con-
ducting survival analysis. Only patients alive and con-
tributing data at landmark time were included in the
analysis. The exposure was evaluated between the index
date and the landmark time whereas the incidence of ED
was only considered after the landmark time point. Two
landmark points were considered in the analysis (1
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and 3 years after diagnosis) based on a previously pub-
lished study [13]. Only patients prescribed more than
6 months of ULT were considered to be exposed. Finally,
we repeated our analyses for pharmacologically treated
ED. All statistical analyses were carried out using STATA
MP 14 (StataCorp LP, College Station, TX, USA).
Results
Our gout cohort consisted of 9653 patients matched to
38,218 controls representing 90,036 and 302,814
person-years of follow-up, respectively. The median
follow-up from index to study end date was calculated
to be 10 years (IQR = 5–13 years). Compared to con-
trols, men with gout were less likely to smoke (15% ver-
sus 22%; p < 0.001), more likely to drink ≥ 10 alcohol
units/week (49% versus 32%, p value < 0.001), and more
likely to be overweight or obese (Table 1). Gout cases
also had a higher prevalence of diabetes mellitus,
hypertension, ischemic heart disease, chronic renal dis-
ease and depression compared to their matched
controls.
A total of 5860 incident ED events were recorded
during the study period after the index date (Table 2).
The absolute rate (AR) of ED reporting among men
with gout was calculated to be 193 (95%CI; 184–202)
per 10,000 person-years. This corresponded to a 0.6%
excess absolute risk and a 31% increased adjusted rela-
tive risk (HR = 1.31; 95%CI 1.24–1.40) compared to
those without gout. Our results remained consistent
when we stratified our analyses by patient characteris-
tics. The absolute rate of pharmacologically treated ED
among men with gout was 107 per 10,000 person years
(95%CI 107–121) with the excess absolute risk of 0.3%
compared with controls (Table 3). However, the risk of
pharmacologically treated ED was not statistically dif-
ferent between cases and controls among younger
population (<45 years) or those with a recorded diagno-
sis of diabetes mellitus or chronic renal failure.
As shown in Table 4, 1616 patients in the 1-year land-
mark analysis and 1091 patients in the 3-year landmark
analysis reported ED during the follow-up period. We
did not find statistically significant differences in the risk
of ED by ULT. Similar findings were also reported for
Table 1 Basic characteristics of the study population
Variable Controls
N = 38,218
Gout cases
N = 9653
p value*
N % N %
Age in years
≤ 34 2774 7.3 712 7.4 0.800
35–44 8900 23.3 2206 22.9
45–54 12,887 33.7 3256 33.7
55–64 13,649 35.7 3479 36.0
Never/ex-smokers 30,010 78.5 8210 85.1 <0.001
Current smoker 8200 21.5 1443 14.9
Never/ex-drinkers 10,703 28.0 1578 16.3 <0.001
Current drinkers (1–9 units/week) 15,420 40.4 3381 35.0
Current drinkers (≥10 units/week) 12,087 31.6 4694 48.6
Body mass index
Normal 10203 26.7 1376 14.3 <0.001
Underweight 332 0.9 42 0.4
Overweight 13,224 34.6 3753 38.9
Obese 6952 18.2 3598 37.3
Missing 7499 19.6 884 9.2
Comorbidities
Ischemic heart disease 2893 7.6 1180 12.2 <0.001
Diabetes 3084 8.1 1470 15.2 <0.001
Hypertension 8210 21.5 4191 43.4 <0.001
Chronic renal disease 1026 2.7 802 8.3 <0.001
Depression 6242 16.3 1894 19.6 <0.001
*Chi-squared test
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pharmacologically treated ED. Those with gout had 1.77
times (95%CI 1.38–2.26) higher relative risk of reporting
ED compared to controls within the second year of gout
diagnosis. The adjusted relative risk decreased in the
years following diagnosis to 1.16 after 5 years of diagno-
sis but was also 1.63 times higher (95%CI 1.24-2.08)
within the year preceding diagnosis (Fig. 1). These esti-
mates remained broadly similar for pharmacologically
treated ED (Fig. 2).
Discussion
In this large nationally representative cohort of men
with gout with more than 10 years of follow-up, we have
provided contemporary, generalisable and population-
based estimates of the absolute risk of ED reporting in
England. Overall we found the risk of ED post-diagnosis
to be 2% per year. Whilst those with gout were 31%
more likely to consult their general practitioner for ED
compared to those without gout, the excess absolute risk
was 0.6% per year. The risk of pharmacologically treated
ED was not statistically different between cases and con-
trols among the younger population (<45 years) or those
with a recorded diagnosis of diabetes or chronic renal
failure. Having more than 6 months of ULT within 1
and 3 years from initial gout diagnosis had no impact
ED reporting. The risk of consulting a GP for ED was
also higher within the year preceding the initial gout
diagnosis.
We have conducted one of the largest studies to pre-
cisely determine the risk of ED among men with gout.
Our study used an open cohort approach, with prospect-
ively recorded data utilising information from primary
care from across England, covering 3% of the total UK
population with similar age and sex distribution to the
population as a whole. Thus these findings are not only
generalisable to England but also to other developed
Table 2 Absolute and relative rate of ED reporting by patient characteristics and comorbidities
Variable Controls Gout cases Adjusteda HR 95% CI Absolute risk
differencebN Rateb 95% CI N Rateb 95% CI
Overall 4124 136.2 132.1 140.4 1736 192.8 184.0 202.1 1.31 1.24 1.40 56.6
Age
≤ 34 68 34.6 27.3 43.9 42 61.4 45.4 83.1 1.20 0.79 1.83 26.8
35–44 548 76.2 70.1 82.8 251 112.6 99.5 127.4 1.18 1.01 1.39 36.4
45–54 1551 146.0 138.9 153.5 653 211.7 196.1 228.6 1.28 1.16 1.41 65.7
55–64 1957 186.3 178.3 194.8 790 262.8 245.1 281.8 1.37 1.25 1.49 76.5
Smoking status
Never/ex-smokers 3281 132.8 128.4 137.5 1487 191.2 181.7 201.1 1.32 1.24 1.41 58.3
Current smoker 843 151.1 141.2 161.6 249 203.2 179.5 230.1 1.29 1.11 1.50 52.2
Alcohol consumption
Never/ex-drinkers 834 112.3 104.9 120.2 283 206.7 183.9 232.2 1.77 1.53 2.05 94.4
Current drinkers (1–9 units/week) 1716 132.6 126.5 139.1 601 184.2 170.1 199.5 1.29 1.17 1.42 51.6
Current drinkers (≥10 units/week) 1574 158.7 151.1 166.8 852 194.9 182.2 208.4 1.21 1.11 1.32 36.2
Body mass index
Normal 943 117.4 110.1 125.1 201 157.8 137.4 181.1 1.34 1.14 1.57 40.4
Underweight 18 67.5 42.5 107.2 - - - - - - - -
Overweight 1659 146.5 139.6 153.7 696 196.5 182.4 211.6 1.33 1.21 1.45 50.0
Obese 1068 170.0 160.1 180.5 712 204.2 189.7 219.7 1.23 1.11 1.35 34.1
Missing 436 99.6 90.7 109.4 126 189.5 159.1 225.6 1.71 1.37 2.14 89.8
Comorbidities
Congestive heart disease 443 174.2 158.7 191.2 253 227.6 201.2 257.5 1.26 1.07 1.47 53.4
Diabetes 946 343.6 322.4 366.2 514 349.4 320.4 380.9 1.05 0.94 1.74 5.8
Hypertension 1347 173.4 164.4 183.0 852 206.8 193.4 221.2 1.18 1.09 1.29 33.4
Chronic renal disease 122 106.3 89.0 127.0 129 149.5 125.8 177.7 1.41 1.10 1.81 43.2
Depression 872 168.5 157.7 180.0 381 216.1 195.4 238.9 1.26 1.11 1.43 47.6
ED erectile dysfunction, CI confidence interval
aMutually adjusted unless stratified
bPer 10,000 person-years
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Table 3 Absolute and relative rate of pharmacologically treated ED by patient characteristics and comorbidities
Variable Controls Gout cases Adjusteda HR 95% CI Absolute risk
differencebN Rateb 95% CI N Rateb 95% CI
Overall 2429 80.2 77.1 83.5 1024 113.7 107.0 120.9 1.36 1.26 1.47 33.5
Age
≤ 34 32 16.3 11.5 23.0 23 33.6 22.4 50.6 1.24 0.67 2.29 17.3
35–44 329 45.7 41.1 51.0 139 62.4 52.8 73.6 1.11 0.89 1.37 16.6
45–54 925 87.1 81.6 92.9 391 126.8 114.8 140.0 1.30 1.15 1.47 39.7
55–64 1143 108.8 102.7 115.3 471 156.7 143.2 171.5 1.46 1.30 1.64 47.9
Smoking status
Never/ex-smokers 1955 79.1 75.7 82.7 891 114.5 107.3 122.3 1.39 1.27 1.51 35.4
Current smoker 474 84.9 77.6 92.9 133 108.5 91.6 128.7 1.23 1.01 1.51 23.6
Alcohol consumption
Never/ex-drinkers 484 65.2 59.6 71.2 154 112.5 96.0 131.7 1.82 1.49 2.21 47.3
Current drinkers (1–9 units/week) 992 76.7 72.0 81.6 321 98.4 88.2 109.8 1.27 1.11 1.44 21.7
Current drinkers (≥10 units/week) 953 96.1 90.2 102.4 549 125.6 115.5 136.5 1.31 1.17 1.46 29.5
Body mass index
Normal 589 73.3 67.6 79.5 116 91.0 75.9 109.2 1.27 1.03 1.56 17.7
Underweight 10 37.5 20.2 69.7 - - - - - - -
Overweight 971 85.8 80.5 91.3 419 118.3 107.5 130.2 1.36 1.21 1.53 32.5
Obese 581 92.5 85.3 100.3 399 114.4 103.7 126.2 1.28 1.12 1.46 21.9
Missing 278 63.5 56.5 71.4 89 133.8 108.7 164.7 1.88 1.43 2.48 70.3
Comorbidities
Congestive heart disease 199 78.2 68.1 89.9 123 110.7 92.7 132.1 1.34 1.06 1.70 32.4
Diabetes 488 177.3 162.2 193.7 264 179.4 159.1 202.4 1.04 0.89 1.21 2.2
Hypertension 737 94.9 88.3 102.0 486 118.0 107.9 128.9 1.24 1.10 1.39 23.1
Chronic renal disease 51 44.4 33.8 58.5 52 60.3 45.9 79.1 1.34 0.90 1.99 15.8
Depression 479 92.6 84.6 101.2 219 124.2 108.8 141.8 1.37 1.16 1.62 31.6
ED erectile dysfunction, HR hazard ratio, CI confidence interval
aMutually adjusted unless stratified
bPer 10,000 person-years
Table 4 Absolute and relative rate of ED among those ever prescribed urate-lowering therapy (ULT)
1-year landmark analysis
Total patients = 9322
ULT exposed = 1249
3-year landmark analysis
Total patients = 8650
ULT exposed = 1787
Gout cases ED events Absolute rateb (95% CI) Adjusted HR (95% CI)a ED events Absolute rateb (95% CI) Adjusted HR (95% CI)a
For overall ED reporting
Not treated 1364 194.8 (184.7–205.4) 1.00 797 196.9 (184.9–209.6) 1.00
Treated with ULT 252 237.1 (209.6–268.3) 1.14 (0.99–1.30) 294 229.1 (204.4–256.9) 1.07 (0.94–1.22)
Pharmacologically treated ED
Not treated 797 113.8 (106.2–122.0) 1.00 548 110.3 (101.5–120) 1.00
Treated with ULT 141 132.8 (112.5–156.5) 1.12 (0.93–1.34) 161 125.5 (107.5–146.4) 1.08 (0.90–1.29)
ED erectile dysfunction, CI confidence interval, HR hazard ratio
aAdjusted for age, BMI, smoking status, alcohol consumption, ischemic heart disease, chronic renal disease, depression, hypertension and diabetes
bPer 10,000 person-years
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nations with comparable health care systems. Our use of
primary care data allowed us to adjust our estimates for
important confounding factors such as smoking status,
alcohol consumption and BMI, which had not been done
in previous studies on the subject. Furthermore, pro-
spective data allowed us to look at the timing of ED in
relation to gout diagnosis, which also has not been pre-
viously demonstrated.
A potential limitation is the use of anonymised data
with no direct link to the patient record and our reliance
on general practitioners entering data accurately. How-
ever, gout diagnosis has been externally validated in
CPRD with a high degree of accuracy [10] so it is un-
likely that there is any major error in our study due to
the misclassification of gout diagnosis. Similarly, validity
and under-reporting of ED due to the reluctance of pa-
tients to seek medical advice may be a concern, however,
our study provides estimates which reflect contemporary
ED reporting and screening practices in primary care,
which form the basis of management. Nonetheless, our
absolute rates of ED are much higher compared to most
studies on the subject [6, 7].
There may be potential ascertainment bias as gout pa-
tients may be more aware of associated comorbidities
and consequently, report more ED compared to those
without gout. However, we believe the impact of this
may be minimal as higher relative risk of ED was also
observed among those with pharmacologically treated
ED and also within the year preceding gout diagnosis.
We also acknowledge the lack of complete data on BMI
which could bias our estimates. Nonetheless, we treated
patients with missing data as a separate category and in-
cluded them in our analysis. The fact that we were able
to adjust for BMI and other lifestyle-related characteris-
tics is an advantage over other large studies on the topic.
Finally, the use of 1- and 3-year landmarks for our ULT
analysis means that our findings are only generalisable
to those alive and contributing data at those landmark
points and prescribed at least 6 months of ULT after
their initial gout diagnosis.
The absolute rate of ED reporting among gout patients
in our cohort was calculated to be 2% per year. This is
much higher than the rate previously reported by two
large registry-based studies from Taiwan (0.1–0.2% per
Fig. 2 Timing of pharmacologically treated ED reporting in relation to gout diagnosis compared to controls
Fig. 1 Timing of ED reporting in relation to gout diagnosis compared to controls
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year) utilising Health Insurance Research Database [6, 7].
This may be because treatment for ED in Taiwan is not
covered by their National Health Insurance program lead-
ing to under-ascertainment of ED. Furthermore, differ-
ences in study population and cultural norms may also
have contributed to ED under-reporting. Overall we ob-
served a 31% increased relative risk of ED among gout pa-
tients compared to controls. Whilst these estimates are in
line with those reported in Southeast Asian studies [6, 7],
a US-based study reported around threefold higher risk of
ED among gout cases [5]. The latter study was based on a
cross-sectional survey of men aged 18–89 years attending
a rheumatology clinic with any form of arthritis, which
may be prone to selection and recall bias. Furthermore,
the finding of this previous study may not be generalisable
to the majority of patients with gout who are managed
exclusively in primary care.
Whilst our study supports most of the findings from
the Taiwanese studies, it is important to note that the
excess absolute risk of ED among gout patients com-
pared to controls is less than 0.6%. Furthermore, we re-
ported no increased risk of ED reporting among those
with diabetes and chronic renal disease, which suggests
stronger influence of those conditions on ED than gout.
Our findings support the likely physiological influence of
hyperuricaemia on vasculature including induction of
vascular smooth muscle proliferation, oxidative stress,
and activation of the renin-angiotensin axis in vascular
beds [14] which begins in asymptomatic hyperuricaemia
before the clinical diagnosis of gout.
Conclusions
Our study has important clinical implications. First, we
have found that men with gout are at a higher risk of
ED compared to the general population. The increased
relative risk is broadly similar when stratified by comor-
bidities suggesting limited interaction with those factors.
These findings may have important implications in plan-
ning a multidisciplinary approach to managing patients
with gout. Second, we observed increased relative risk of
ED within the year before gout diagnosis. Therefore it
may be more reasonable to suspect hyperuricaemia as
one of the underlying cause of ED among men with
asymptomatic hyperuricaemia but are yet to develop
clinically apparent gout.
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